COST-EFFICACY ANALYSIS OF GEFITINIB EFFICACY IN PATIENTS WITH NON OPERABLE NON SMALL CELL LUNG CANCER

Drug treatment of disseminated non small cell lung cancer  (NSCLC) is an actual  issue today.  Both clinical and economic efficacy analysis is needed for optimal therapy selection. We performed economic efficacy assessment of  gefitinib (G.)  therapy in patients with non operable NSCLC who hase no EGFR mutation using Markov model based  on results of clinical studies  conducted in N.N. Petrov Research Institute of Oncology.

G. increases  overall survival of patients with NSCLC with EGFR mutation by 1,05 year. Cost/efficacy coefficient for  G. in patients with  EGFR mutation is 934  800  rub  per  1 acquired year  of  life. Therapy  with  G just for  patients with  genetically  proven  mutation is dominating strategy when  compared to  therapy for  all NSCLC patients  irrespectively to  mutation status (saving  211600 – 251800  rub per  1  patient taking  into  account equal clinical efficacy). Therapy  with  G. is economically  justifying  strategy when  compared to chemotherapy (additional costs coefficient 960700 – 1010000 rub per 1 gained year of life). Thus, EGFR mutation testing with subsequent G. therapy in non  operable NSCLC patients not only prolongs patient’s life but also has  acceptable level of medical expenses.

1. Государственный реестр цен на лекарственные средства, относящиеся к перечню жизненно необходимых и важнейших лекарственных средств (ЖНВЛС), по состоянию на 26 июля 2011 года || htpp: //www.ROS-MED.INFO.

2. Моисеенко В.М., Проценко С.А., Семенов И.И., Моисеенко Ф.В., Левченко Е.В., Мацко Д.E., Иванцов А.О., Иевлева А.Г., Митюшкина Н.В., Того А.В., Имянитов Е.Н. Эффективность гефитиниба в первой линии терапии неоперабельных аденокарцином лёгкого, содержащих мутацию в гене EGFR: исследование II фазы // Вопросы онкологии. – 2010. – Т. 56. – № 1. – С. 20-23.

3. Приложения к Генеральному тарифному соглашению по тарифам на медицинскую помощь (медицинские услуги) и условиям оплаты медицинской помощи, оказываемой в рамках действующей Территориальной программы обязательного медицинского страхования граждан Российской Федерации в Санкт-Петербурге на 2011 г. // Информационный портал ОМС Санкт-Петербурга. URL: http://www.spboms.ru/kiop/getdoc?doc_id=4778 (доступ 01.06.2011).

4. Ягудина Р.И. Определение «порога готовности платить» в России, в Европейских странах и в странах СНГ / Р.И. Ягудина, А.Ю. Куликов, Т. Нгуен // Современная фармакоэкономика и фармакоэпидемология. 2011. Т.4. С. 7-12.

5. Appraising life extending, end of life treatments // NICE 2008. URL: www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdf (accessed 23.03.2012).

6. Brock D. Ethical and value issues in insurance coverage for cancer treatment // The Oncologist. 2010. Vol. 15. Suppl. 1. P. 36–42.

7. Fukuoka M. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non–small-cell lung cancer in Asia (IPASS) / Fukuoka M., Wu Y.-L., Thongprasert S. et al. // J. Clin. Oncol. 2011. Vol. 29. P. 2866-2874.

8. Gridelli С. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence / С. Gridelli, F. De Marinis, M. Di Maio et al. // Lung Cancer. 2011. Vol.71. P. 249-257.

9. Horgan A. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer / A. Horgan, P. Bradbury, E. Amir et al. // Ann. Onc. 2011. Vol. 22. P. 1805–1811.

10. Malin J. Wrestling with the high price of cancer care: should we control costs by Individuals’ ability to pay or society’s willingness to pay? // J. Clin. Oncol. - 2010. Vol. 28. P. 3212-3214.

11. Moiseyenko V. M., Procenko S. A., Levchenko E. V., Barchuk A.S., Moiseyenko F.V., Iyevleva A.G., Mitiushkina N.V., Togo A.V., Semionov I.I., Ivantsov A.O., Matsko D.E., Imyanitov E.N. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma // Onkologie. 2010. Vol. 33. №5. Р. 231-238.

12. Nadler E. S. Do oncologists believe new cancer drugs offer good value? / E.S. Nadler, B. Eckert, P. Neumann // J. Clin. Oncol. 2005. Vol. 23. Р. 6011.

13. Neumann P. Cancer therapy costs influence treatment: a national survey of oncologists/ P. Neumann, J. Palmer, E. Nadler et al. // Health Aff. 2010. Vol. 29. P. 196-202.

14. Petrelli N. Clinical Cancer Advances 2009: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology / N. Petrelli, E. Winer, J. Brahmer, et al. // J. Clin. Oncol. 2009. Vol. 27. P. 6052-6069.

15. Rocchi A. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond / A. Rocchi, D. Menon, S. Verma, E. Miller // Value Health. 2008. Vol. 11. P. 771–783.

16. World Health Organization. Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health. Geneva (Switzerland) // World Health Organization. 2003. URL: http:// www.who.int/macrohealth/infocentre/advocacy/en/investinginhealth02052003.pdf (accessed 23.03.2012).